MedTrace Logo

Ex Vivo Human Thrombosis Chamber Study

NCT00935506 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2011-02-23

No results posted yet for this study

Summary

Purpose of study is to evaluate a thrombosis chamber model

Conditions

Interventions

DRUG

Clopidogrel

Tablets, Oral, 75 mg, Once daily, 8 days

DRUG

Aspirin

Tablets, Oral, 325 mg, Once daily, 8 days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00935506 on ClinicalTrials.gov